Partnering with exceptional research teams worldwide

Vita Therapeutics is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell technology. Vita utilizes iPSCs to engineer specific cell types designed to replace those that are defective in patients, focusing on two distinct methodologies to deliver these cells: an autologous approach, a patient-specific therapy; and a hypoimmunogenic approach, a universal cell designed to be used for all patients. Vita is committed to delivering long-term disease-modifying cell-engineered treatments for patients with high unmet medical needs.

Vita Therapeutics is advancing a novel approach to treating a localized form of muscular dystrophy with a cell therapy that combines the power of gene correction and induced pluripotent stem cell technology. Vita utilizes iPSCs to engineer specific cell types designed to replace those that are defective in patients, focusing on two distinct methodologies to deliver these cells: an autologous approach, a patient-specific therapy; and a hypoimmunogenic approach, a universal cell designed to be used for all patients. Vita is committed to delivering long-term disease-modifying cell-engineered treatments for patients with high unmet medical needs.

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). They are an exceptionally well-explored therapeutic class, encompassing 3 FDA-approved medications evaluated in more than 3,000 clinical trials. Tornado Therapeutics is developing safer, more effective mTOR inhibitors with novel selectivity profiles to extend human healthspan. Its most advanced asset is currently moving into IND-enabling studies, while a second asset is undergoing preclinical efficacy testing.

Oviva Therapeutics is developing a first-in-class therapeutic agent targeting the AMH/AMR2 axis to extend ovarian function and improve female healthspan. Oviva’s asset is in advanced preclinical stage; this agent suppresses folliculogenesis, the process wherein follicles within the ovary – each housing a single egg – mature to ultimately ovulate. Through preservation of the ovarian reserve — the number of eggs housed in the ovaries — Oviva aims to prolong the functional lifespan of the ovary, prevent the negative health consequences that result from ovarian decline, and support systemic health in women.